A Phase 2 interventional study of Belzutifan in Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor and Von Hippel-Lindau Disease, sponsored by Merck Sharp & Dohme LLC. Recruiting at 86 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Pheochromocytoma with a site in United States — 19 open to participants now, 28 under way, none of them phase 3. Pheochromocytoma · United States.
Among the 69 studies in Pheochromocytoma with a site in United States, this one is the 4th largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2021, is one of 30 in phase 2, reaches primary completion later than 23 of the 25 other live ones, and was the 58th registered.
158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.
Browse Pheochromocytoma studies →19 of the 69 studies in Pheochromocytoma with a site in United States are open now. Recruiting first, the newest first:
Anusha Kalbasi · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Pheochromocytoma studies recruiting now, 22 (51%) set no upper age limit and 6 (14%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 36 · Phase 3 3
First in 1988; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 355 is above the median of 37 across 87 interventional studies indexed under Pheochromocytoma.
Median enrollment 31 across the 52 interventional studies, 370 across the 10 observational. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 1 study filed under Pheochromocytoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Pheochromocytoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05636540Heather WachtelIn Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | 2026-12-31 |
| NCT03839498Columbia UniversityStudy of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | 2027-01 |
| NCT03541720St. Jude Children's Research Hospital18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | 2027-01-01 |
| NCT03946527Antonio FojoLAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | 2027-03 |
| NCT00107289Memorial Sloan Kettering Cancer CenterIodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Pheochromocytoma with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
The main inclusion criteria include but are not limited to the following:
Cohort B1: VHL Disease-associated tumors:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
Drug: Belzutifan
Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
Also known as: MK-6482, WELIREG™
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
ORR is the percentage of participants with complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD, at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression) or death due to any cause, whichever occurs first.
Time frame: Up to approximately 5.5 years
Duration of Response (DOR) as Assessed by BICR
DOR is the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
Time frame: Up to approximately 5.5 years
Time to Response (TTR) as Assessed by BICR
TTR is defined as the time from first dose of belzutifan to first documented evidence of CR or PR.
Time frame: Up to approximately 5.5 years
Disease Control Rate (DCR) as Assessed by BICR
Disease control is a confirmed CR, PR, or stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study).
Time frame: Up to approximately 5.5 years
Progressive Free Survival (PFS) as Assessed by BICR
PFS is the time from first dose of belzutifan to the first documented PD or death from any cause, whichever occurs first.
Time frame: Up to approximately 5.5 years
Overall Survival (OS)
OS is the time from first dose of belzutifan until death from any cause.
Time frame: Up to approximately 5.5 years
Number of Participants Who Experience an Adverse Event (AE)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to approximately 5.5 years
Number of Participants Who Discontinue Study Treatment Due to an AE
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinue study treatment due to an AE will be presented.
Time frame: Up to approximately 5.5 years
Time to Surgery (TTS)
TTS is defined as the time from the first dose of belzutifan to the first documented surgical intervention or tumor reduction procedure.
Time frame: Up to approximately 5.5 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Aug 2021 (actual). Primary completion is estimated for Nov 2032, 135 months after the start.
Of 28 phase 2 interventional studies under Pheochromocytoma, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 157. This study's planned 135 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belzutifan